| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
123,940,000 |
| Market
Cap: |
202.02(M) |
| Last
Volume: |
38,851 |
Avg
Vol: |
19,408 |
| 52
Week Range: |
$1.63 - $1.63 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products in China, the U.S., and throughout the world.. In China, Co.'s first commercial product, EVOMELA® is approved for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The other core hematology/oncology assets in our pipeline include: CNCT19, which is being developed as a potential treatment for patients with hematological malignancies which express CD19 including, B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
459,671 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,587,610 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
14 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Huang James |
Director |
– • – |
2022-09-08 |
4 |
B |
$4.28 |
$142,627 |
I/I |
33,300 |
371,517 |
2.1 |
-55% |
|
| Huang James |
Director |
– • – |
2022-09-07 |
4 |
B |
$4.00 |
$12,433 |
I/I |
3,111 |
338,217 |
2.1 |
-52% |
|
| Huang James |
Director |
– • – |
2022-09-06 |
4 |
B |
$3.89 |
$74,601 |
I/I |
19,162 |
335,106 |
2.1 |
-53% |
|
| Huang James |
Director |
– • – |
2022-09-02 |
4 |
B |
$3.74 |
$1,497 |
I/I |
400 |
315,944 |
2.02 |
-45% |
|
| Huang James |
Director |
– • – |
2022-09-01 |
4 |
B |
$3.72 |
$44,008 |
I/I |
11,821 |
315,544 |
2.1 |
-48% |
|
| Huang James |
Director |
– • – |
2022-08-31 |
4 |
B |
$3.75 |
$93,531 |
I/I |
24,975 |
303,723 |
2.1 |
-46% |
|
| Huang James |
Director |
– • – |
2022-08-26 |
4 |
B |
$3.75 |
$148,179 |
I/I |
39,527 |
278,748 |
2.1 |
-49% |
|
| Huang James |
Director |
– • – |
2022-08-24 |
4 |
B |
$3.75 |
$18,751 |
I/I |
5,000 |
239,221 |
2.1 |
-48% |
|
| Huang James |
Director |
– • – |
2022-08-23 |
4 |
B |
$3.50 |
$139,992 |
I/I |
40,000 |
234,221 |
2.1 |
-45% |
|
| Huang James |
Director |
– • – |
2022-08-22 |
4 |
B |
$3.46 |
$80,038 |
I/I |
23,105 |
194,221 |
2.1 |
-47% |
|
| Huang James |
Director |
– • – |
2022-08-19 |
4 |
B |
$3.27 |
$559,447 |
I/I |
171,116 |
171,116 |
2.1 |
-49% |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2022-06-15 |
4 |
B |
$3.18 |
$159,000 |
D/D |
50,000 |
644,553 |
3.23 |
-37% |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2022-06-14 |
4 |
B |
$3.06 |
$6,414 |
D/D |
2,096 |
594,553 |
3.15 |
-39% |
|
| He Wei-Wu |
Chairman and CEO |
• • • |
2022-06-13 |
4 |
B |
$2.97 |
$107,092 |
D/D |
36,058 |
592,457 |
3.23 |
-35% |
|
| He Wei-Wu |
Chairman and CEO |
• • – |
2021-11-18 |
4 |
B |
$0.98 |
$196,000 |
D/D |
200,000 |
5,558,472 |
2.81 |
-25% |
|
| He Wei-Wu |
Chairman and CEO |
• • – |
2021-11-17 |
4 |
B |
$0.99 |
$198,000 |
D/D |
200,000 |
5,362,569 |
2.81 |
-17% |
|
| He Wei-Wu |
Chairman and CEO |
• • – |
2021-08-19 |
4 |
B |
$1.26 |
$226,800 |
D/D |
180,000 |
5,163,994 |
2.81 |
-34% |
|
| He Wei-Wu |
Chairman and CEO |
• • – |
2021-08-18 |
4 |
B |
$1.29 |
$387,000 |
D/D |
300,000 |
4,983,994 |
2.81 |
-38% |
|
| He Wei-Wu |
Chairman and CEO |
• • – |
2021-03-26 |
4 |
B |
$2.05 |
$6,150,000 |
I/I |
3,000,000 |
3,000,000 |
2.66 |
-42% |
|
| He Wei-Wu |
Chairman and CEO |
• • – |
2020-12-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
380,000 |
4,683,994 |
|
- |
|
| Xu Weihao |
Chief Financial Officer |
• – – |
2020-12-17 |
4 |
B |
$2.63 |
$10,537 |
I/I |
4,000 |
10,000 |
1.99 |
-33% |
|
| Xu Weihao |
Chief Financial OfficerOfficer |
• – – |
2020-12-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,000 |
|
-26% |
|
| Xu Weihao |
Chief Financial Officer |
• – – |
2020-12-16 |
4 |
B |
$2.44 |
$4,880 |
I/I |
2,000 |
6,000 |
1.91 |
-26% |
|
| He Wei-Wu |
Chairman and CEO |
• • – |
2020-11-23 |
4 |
B |
$2.18 |
$218,000 |
D/D |
100,000 |
5,063,994 |
2.81 |
-4% |
|
| He Wei-Wu |
Chairman and CEO |
• • – |
2020-11-20 |
4 |
B |
$2.12 |
$270,239 |
D/D |
127,471 |
4,963,994 |
2.81 |
-3% |
|
83 Records found
|
|
Page 1 of 4 |
|
|
